2.Sarcoidosis Presenting as Tenosynovitis of Both Ankles.
Seung Ki KWOK ; Soo Hong SEO ; Ji Hyeon JU ; Chong Hyeon YOON ; Sung Hwan PARK ; Ho Youn KIM
The Journal of the Korean Rheumatism Association 2007;14(3):307-309
No Abstract available.
Ankle*
;
Sarcoidosis*
;
Tenosynovitis*
5.Echocardiographic Evaluation of Axial Spondyloarthritis in Korea: Data From the Catholic Axial Spondyloarthritis Cohort
Hong Ki MIN ; Jennifer LEE ; Ji Hyeon JU ; Seung Ki KWOK ; Ho Joong YOUN ; Sung Hwan PARK
Journal of Rheumatic Diseases 2020;27(1):30-36
OBJECTIVE:
Axial spondyloarthritis (axSpA) is often accompanied by cardiac manifestations, such as valvular heart disease. In this prospective cohort study, we evaluated the incidence of cardiac abnormalities in Korean axSpA patients by echocardiography.
METHODS:
AxSpA patients were prospectively recruited from a single tertiary hospital. Baseline demographic, clinical, radiographic, and echocardiographic data were collected at the time of enrollment. Echocardiography evaluations were performed with a focus on valvular heart disease and systolic and diastolic function. Logistic regression analyses were used to identify factors associated with diastolic dysfunction in axSpA.
RESULTS:
A total of 357 axSpA patients were included in the analyses, of whom 78 (21.8%) exhibited diastolic dysfunction, with no reports of systolic dysfunction. Thirteen patients (3.6%) had valvular heart disease, and aortic valve regurgitation (n=5) and mitral valve regurgitation (n=6) were most common. Multivariable logistic regression analyses indicated that older age and higher body mass index (BMI) were positively associated with diastolic dysfunction, whereas human leukocyte antigen (HLA)-B27 positivity was negatively associated with diastolic dysfunction.
CONCLUSION
Valvular heart disease is infrequent in Korean axSpA patients. However, diastolic dysfunction is common in axSpA patients, and is significantly associated with older age, higher BMI, and HLA-B27.
6.Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
Seung Min JUNG ; Seung Ki KWOK ; Ji Hyeon JU ; Yong Beom PARK ; Sung Hwan PARK
The Korean Journal of Internal Medicine 2019;34(3):669-677
BACKGROUND/AIMS:
Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data.
METHODS:
Patients with seropositive RA were selected from the health insurance database containing all citizens' medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods.
RESULTS:
Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546).
CONCLUSIONS
This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.
7.Review of Sjogren's Syndrome for Primary Physicians.
Korean Journal of Medicine 2015;89(3):291-294
Sjogren's syndrome is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands resulting in a dry mouth and eyes. The disease can present either alone or in association with other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and inflammatory myopathy. In addition to symptoms caused by exocrinopathy, about half of patients present with extraglandular (systemic) manifestations including arthritis, Raynaud's phenomenon, lymphadenopathy, vasculitis, peripheral neuropathy, and interstitial nephritis. Patients often suffer from severe fatigue, myalgia, and dryness, which lead to a poor quality of life. Physicians should be aware of the increased risk of lymphoma development in patients with Sjogren's syndrome. Currently, there are no drugs available that are able to improve the natural course of disease, making symptom relief the primary goal of therapy. Currently, pilocarpine is the only drug clinically proven for the treatment of dry eyes and mouth in patients with Sjogren's syndrome.
Arthritis
;
Arthritis, Rheumatoid
;
Autoimmune Diseases
;
Exocrine Glands
;
Fatigue
;
Humans
;
Lupus Erythematosus, Systemic
;
Lymphatic Diseases
;
Lymphoma
;
Mouth
;
Myalgia
;
Myositis
;
Nephritis, Interstitial
;
Peripheral Nervous System Diseases
;
Pilocarpine
;
Quality of Life
;
Scleroderma, Systemic
;
Sjogren's Syndrome*
;
Vasculitis
8.MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis.
Dong Gun LEE ; Jung Won WOO ; Seung Ki KWOK ; Mi La CHO ; Sung Hwan PARK
Experimental & Molecular Medicine 2013;45(4):e20-
Myeloid-related protein (MRP)8/MRP14 is an endogenous Toll-like receptor 4 (TLR4) ligand and is abundant in synovial fluid (SF) of rheumatoid arthritis (RA) patients. Belonging to damage-associated molecular patterns, it amplifies proinflammatory mediators and facilitates a wide range of inflammatory and autoimmune diseases. Interleukin (IL)-17-producing T-helper (Th)17 cells have a crucial role in RA pathogenesis, and IL-6 is the key factor promoting Th17 differentiation. We investigated whether the level of MRP8/MRP14 is positively associated with IL-6 and IL-17 levels in RA SF and found that MRP8/MRP14 level had a significant correlation with IL-6 and IL-17 levels in RA SF. We also observed that MRP8-induced IL-17 production by peripheral blood mononuclear cells but MRP14 did not. Upon stimulation with MRP8, IL-6 production was enhanced by RA fibroblast-like synoviocytes (FLS) and was further elevated by coculturing RA FLS with activated CD4+ T cells. Moreover, we demonstrated that MRP8-activated IL-6 production by RA FLS promoted differentiation of Th17 cells using the coculture system consisting of CD4+ T cells and RA FLS. In addition, IL-6 blockade attenuated Th17 polarization of CD4+ T cells in the cocultures. Inhibitor studies revealed that MRP8 increased IL-6 production in RA FLS via TLR4/phosphoinositide 3-kinase/nuclear factor-kappaB and mitogen-activated protein kinase signaling pathways. Our results show that MRP8 has a crucial role in stimulating IL-6 expression by RA FLS, and subsequently promotes Th17 differentiation in RA, suggesting that neutralizing MRP8 level in RA synovium may be an effective therapeutic strategy in RA treatment.
ATP-Binding Cassette Transporters/*metabolism
;
Adult
;
Aged
;
Arthritis, Rheumatoid/*pathology
;
CD4-Positive T-Lymphocytes/metabolism
;
Calgranulin B/metabolism
;
Cell Differentiation/*immunology
;
Fibroblasts/*metabolism/pathology
;
Humans
;
Inflammation Mediators/metabolism
;
Interleukin-17/metabolism
;
Interleukin-6/*biosynthesis
;
Middle Aged
;
Signal Transduction/immunology
;
Synovial Fluid/cytology
;
Synovial Membrane/metabolism/pathology
;
Th17 Cells/*pathology
;
Toll-Like Receptor 4/metabolism
;
*Up-Regulation
9.Unusual Sjogren's Syndrome with Bilateral Parotid Cysts.
Bommie Florence SEO ; Rock Kuen JU ; Seung Ki KWOK ; Deuk Young OH
Archives of Craniofacial Surgery 2014;15(2):98-101
Sjogren's syndrome is a chronic autoimmune exocrinopathy that destroys salivary and lacrimal gland tissue. We report an unusual case of this disease in a 54-year-old woman who presented with multiple and bilateral parotid cystic masses. The multiple, small, bead-like cysts were clearly evident in the computed tomography sections in this patient, a visible reminder that this may be the initial presentation in a patient with Sjogren's syndrome. As the case illustrates, Sjogren's syndrome should be included in the differential diagnosis of multiple and bilateral cystic parotid lesions.
Diagnosis, Differential
;
Female
;
Humans
;
Lacrimal Apparatus
;
Middle Aged
;
Parotid Gland
;
Rare Diseases
;
Sjogren's Syndrome*
10.Unusual Sjogren's Syndrome with Bilateral Parotid Cysts.
Bommie Florence SEO ; Rock Kuen JU ; Seung Ki KWOK ; Deuk Young OH
Archives of Craniofacial Surgery 2014;15(2):98-101
Sjogren's syndrome is a chronic autoimmune exocrinopathy that destroys salivary and lacrimal gland tissue. We report an unusual case of this disease in a 54-year-old woman who presented with multiple and bilateral parotid cystic masses. The multiple, small, bead-like cysts were clearly evident in the computed tomography sections in this patient, a visible reminder that this may be the initial presentation in a patient with Sjogren's syndrome. As the case illustrates, Sjogren's syndrome should be included in the differential diagnosis of multiple and bilateral cystic parotid lesions.
Diagnosis, Differential
;
Female
;
Humans
;
Lacrimal Apparatus
;
Middle Aged
;
Parotid Gland
;
Rare Diseases
;
Sjogren's Syndrome*